An interventional study of L. plantarum 299 and L. plantarum 299v (+maltodextrin) and Maltodextrin in Clostridium Difficile Colonisation and Impact of Enteral Probiotics on Certain Lab Parameters, sponsored by Region Skane. Terminated at 4 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-05.
Sponsored by Region Skane · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Symptoms of Clostridium difficile infection is almost always induced as a complication to the use of antibiotics. Most ICU patients are given antibiotics.
Probiotics has the ability to improve conditions in the gut and it has been shown in some smaller studies that overgrowth of C. difficile can be reduced or prevented.
In this study the intention is to show with sufficient statistical power that a mixture of two otherwise well studied probiotic strains reduces or prevents the incidence of emerging colonisation with C. difficile in critical ill patients on antibiotics.
Half of the patients will be given a mixture of Lactobacillus plantarum 299 and Lactobacillus plantarum 299v twice daily and the rest a placebo mixture.
Rectal swabs or faeces will be analysed for C.difficile and its toxins and the incidence of new cases will be compared for the two groups.
White blood cells (WBC´s), C reactive protein (CRP), lactate, urea, and creatinine will be followed daily as well as antibiotics, corticosteroids and all acid reducing medication.
Nutrition, enteral and total, and bowel habits will be recorded.
Infections with Clostridium difficile is considered to be the most frequent health care associated bacterial infection. Almost all cases are connected to the use of antibiotics.
The spectra of symptoms of infection reaches from loose stools to sepsis and death. It is estimated that about 5% of the population are carriers without symptoms.
Elderly people are more likely to be diagnosed with C. difficile infections and as about 50 % of ICU admissions (at least in Sweden) are patients aged 64 years or older C. difficile is also an ICU issue.
Probiotic bacteria given to antibiotic treated patients results in fever cases of infection with C. difficile as we and others have shown in some small studies. Due to a low statistical power in our former study this multicentre study is calculated to be large enough to fulfil statistical requirements.
Adult patients with an expected length of stay in intensive care for three days or more can be included.
Primary objective is to find emerging cases of colonisation with C. difficile and consequent symptoms of infection such as diarrhoea.
Cultures and toxin analyses will be taken at inclusion and every second day till day 13 and then every third or fourth day depending on length of ICU stay. Positive cases will be given antibiotics according to normal routines.
No other cultures are collected per protocol but all cultures will be recorded and results will be analysed in order to find any connection between treatment and reduction of secondary infections.
In our earlier small study we found an improved and normalised gut barrier function for those patients that were given probiotic bacteria compared to a worsened, scattered pattern for the placebo group. This is probably why we found that inflammatory parameters improved for the probiotics group while those parameters remained elevated for the control patients. The same goes for creatinine, urea and lactate. This is why we will record those parameters together with blood gas analyses in this expanded study.
Antibiotics and medication with corticosteroids, proton pump inhibitors or other acid reducing preparations, All nutritive prescriptions (enteral formulas and IV solutions as well as medical preparations containing glucose or fat) will be recorded and compared to actually given nutrients.
Bowel movements frequency and consistency will be recorded and compared between groups.
Region Skane is the lead sponsor of 386 studies on the registry; 122 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will be given a mixture of maltodextrin ( a starch product often used i alimentary products) and two strains of probiotic bacteria ( L. plantarum 299 and L. plantarum 299v ) dissolved in water through a nasogastric tube. Patients randomized 1:1 between groups
Dietary Supplement: L. plantarum 299 and L. plantarum 299v (+maltodextrin)
Patients will be given only the dissolved maltodextrin in water through the nasogastric tube. Patients randomized 1:1 between groups
Other: Maltodextrin
Drug page: Lactobacillus plantarum 299Studies of Lactobacillus plantarum 299Lactobacillus plantarum 299 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
A suspension of Lactobacillus plantarum 299 and Lactobacillus plantarum 299v together with maltodextrin is distributed to the patients twice a day.
Also known as: Lactobacillus plantarum 299, Lactobacillus plantarum 299v, Maltodextrin
A suspension of maltodextrin (as placebo control) is distributed to the patients twice a day.
Differences in emerging cases of Clostridium difficile
Emerging cases of Clostridium difficile, identified as positive cultures and/or toxin tests
Time frame: Throughout the ICU stay, expected mean LOS 10 days
White blood cells
Samples taken at admission or inclusion and then daily
Time frame: Throughout the ICU , expected mean LOS 10 days
C Reactive Protein
Samples taken at admission or inclusion and then daily
Time frame: Throughout the ICU , expected mean LOS 10 days
Creatinine
Samples taken at admission or inclusion and then daily
Time frame: Throughout the ICU , expected mean LOS 10 days
Urea
Samples taken at admission or inclusion and then daily
Time frame: Throughout the ICU , expected mean LOS 10 days
Lactate
Samples taken at admission or inclusion and then daily
Time frame: Throughout the ICU , expected mean LOS 10 days
Ventilator days
Records are held for how long the patients require mechanical ventilation
Time frame: Throughout the ICU stay, expected mean LOS 10 days
Length of stay ICU
Length of stay is recorded for the ICU as well as for the Hospital stay
Time frame: Length of ICU stay, about 10 days in accordance with a prior similar study
Length of Hospital stay
Length of stay is recorded for the Hospital as well as for the ICU stay
Time frame: Within six months from date of ICU admission
Survival
For participating patients the status of survival or non survival at days 28 and 180 (six months) will be recorded
Time frame: Six months
Diarrhea and obstipation
As ICU patients tend to display diarrhea as well as obstipation the frequency and consistency of stools will be recorded. Probiotics are anticipated to stabilise bowel function
Time frame: Throughout the ICU stay, expected mean LOS 10 days
The record gives a start of Jun 2012, a primary completion of Jun 2017 and a completion of Oct 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lactobacillus plantarum 299